A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Ciclosporin (Primary) ; Verapamil (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 08 Mar 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Mar 2019.
- 08 Mar 2017 Status changed from not yet recruiting to recruiting.
- 11 Jan 2017 New trial record